CAR T Cell Immunotherapy
T cells are fighter cells that are a normal part of our immune system. They normally roam throughout the body to seek out and attack abnormal cells. CAR T cell (or Adoptive T cell) therapy aims to improve the way natural T cells function. With this therapy, some of a patient's T cells are removed from their body, and are altered so they can fight cancer. It is called CAR T cell therapy because a lab-made protein, a CAR protein, is added into the patient’s own T cells. The CAR protein helps T cells find and target cancer cells to be killed. The new CAR T cells are injected back into the patient’s body to go to work. Some researchers have called this “a living drug” since the T cells can divide and give rise to more T cells in a self-limiting chain reaction.
Immunotherapy is one of the most exciting areas of new discoveries and treatments for different kinds of cancer. Understanding how the immune system works is opening the doors to developing new treatments that are changing the way we think about and treat cancer. On this episode, guest host Linda House is joined by Dr. Gerald Messerschmidt to talk about immunotherapy and its new advancements in recent years. Elizabeth Franklin also joins the program to discuss barriers and access to quality care for patients with cancer.
Each CAR T cell infusion is individual, created from the patient’s own cells. This is designed as a one-time treatment. It can continue to be active in the body for a long time. There may be serious side effects.
The Food and Drug Administration (FDA) approved tisagenlecleucel (Kymriah™) as the first CAR T cell therapy. It is for people up to age 25 with relapsed or recurrent acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma. The second approved CAR T cell therapy is axicabtagene ciloleucel (Yescarta™). It is used in people with large B-cell lymphomas whose cancer has progressed. Large B-cell lymphomas include large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and transformed follicular lymphoma. The third approved drug is brexucabtagene autoleucel (Tecartus™). It is used to treat people with relapsed or refractory mantle cell lymphoma (MCL) who have had two or more prior treatments.
Right now, CAR T therapy is a very complex and expensive cancer treatment. It is only available at a few dozen cancer centers. Ask if your insurance will cover the drug and hospital costs. Ask if you qualify to get this therapy as part of a clinical trial where the drug cost is covered. You may have to travel long distances to get this therapy. Ask if you can get assistance to cover travel, lodging, and food costs for you and a caregiver. Call 888-793-9355 or visit www.CancerSupportCommunity.org/Cost for more help on coping with cancer costs.
Looking for information on Immunotherapy?
CAR-T cell therapy is a revolutionary treatment approach that is bringing new hope to multiple myeloma patients. Results of an early phase study were described by Reuters as “unheard of” and an industry paper called them “jaw-dropping.” On the show to help us find out all about this exciting new approach are Cherie Rineker who has been living with multiple myeloma for over five years and is participating in a clinical trial exploring this new treatment, and Dr. Jesus Berdeja, lead investigator of that study.
No one should have to face cancer alone.
The Cancer Support Community is here to help you by offering free support and counseling for cancer patients or their loved ones by phone and online: